Fundraising FoxPolyplus
2 known investors
Find your way into Polyplus
Polyplus (a Sartorius company) develops FectoVIR-LV, an animal-component-free transfection reagent for producing lentiviral vectors in suspension HEK-293 cells at large manufacturing scale. It targets cell therapy producers, including those making CAR-T and other allogenic or autologous therapies, in the biomanufacturing sector.
Investors · 2
ARCHIMED Japanlisted by ARCHIMED JapanLyon · $10.8M – $1.1B
How we know: ARCHIMED Japan's portfolio page · Not right? Tell us
Warburg PincusreportedNew York
How we know: funding news · Not right? Tell us
In the news
Frequently asked questions
- What does Polyplus do?
- Polyplus (a Sartorius company) develops FectoVIR-LV, an animal-component-free transfection reagent for producing lentiviral vectors in suspension HEK-293 cells at large manufacturing scale. It targets cell therapy producers, including those making CAR-T and other allogenic or autologous therapies, in the biomanufacturing sector.
- Who are Polyplus's investors?
- Polyplus's investors include ARCHIMED Japan, Warburg Pincus.